Tuhura Biosciences, Inc.
Clinical trials sponsored by Tuhura Biosciences, Inc., explained in plain language.
-
New combo therapy aims to fight hard-to-treat skin cancer
Disease control Recruiting nowThis early-stage trial tests whether adding an experimental drug, IFx-Hu2.0, to the standard immunotherapy pembrolizumab is safe and doable for people with advanced Merkel cell carcinoma that has spread. Nine adults will receive an injection of IFx-Hu2.0 directly into a tumor, fo…
Phase: PHASE1 • Sponsor: TuHURA Biosciences, Inc. • Aim: Disease control
Last updated May 03, 2026 16:28 UTC
-
New combo therapy shows promise against rare skin cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (IFx-Hu2.0) to a standard immunotherapy (pembrolizumab) can shrink tumors better than placebo plus pembrolizumab in people with advanced or metastatic Merkel cell carcinoma. About 118 adults with this rare skin cancer will rece…
Phase: PHASE2, PHASE3 • Sponsor: TuHURA Biosciences, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC